TGF-beta/Smad inhibitors are a class of molecular agents designed to modulate the transforming growth factor-beta (TGF-β)/Smad signaling cascade, one of the most evolutionarily conserved and functionally pleiotropic pathways in eukaryotic cells. Over the past three decades, research into these inhibitors has exploded, driven by the pathway’s dual role in tissue homeostasis and disease pathogenesis—acting as a tumor suppressor in early-stage cancer while promoting metastasis and drug resistance in advanced malignancies, and mediating excessive extracellular matrix (ECM) deposition in fibrotic disorders. This review focuses on the scientific underpinnings of TGF-beta/Smad inhibitors, their molecular targeting strategies, preclinical efficacy in disease models, and emerging challenges in translational research.
TGF-beta/Smad Inibitori/Attivatori (TGF-beta/Smad Inhibitors/Activators)
Altro TGF-beta/Smad Inibitori
Prodotti selettivi di isoforme
| N. Cat. | Nome del prodotto | Informazioni | Citazioni di utilizzo del prodotto | Validazioni del prodotto |
|---|---|---|---|---|
| S1067 | SB431542 | SB431542 è un inibitore potente e selettivo di ALK5 con IC50 di 94 nM in un saggio senza cellule, 100 volte più selettivo per ALK5 rispetto a p38 MAPK e altre chinasi. |
|
|
| S7223 | RepSox (E-616452) | RepSox (E-616452, SJN 2511, ALK5 Inhibitor II) è un inibitore potente e selettivo di TGFβR-1/ALK5 con una IC50 di 23 nM e 4 nM rispettivamente per il legame dell'ATP ad ALK5 e l'autofosforilazione di ALK5 in saggi acellulari. |
|
|
| S7530 | Vactosertib (TEW-7197) | Vactosertib (TEW-7197, EW-7197) è un inibitore del recettore TGF-β ALK4/ALK5 altamente potente, selettivo e biodisponibile per via orale con IC50 rispettivamente di 13 nM e 11 nM. Fase 1. |
|
|
| S2618 | LDN-193189 | LDN-193189 (DM3189) è un inibitore selettivo della segnalazione BMP, inibisce ALK1, ALK2, ALK3 e ALK6 con IC50 di 0,8 nM, 0,8 nM, 5,3 nM e 16,7 nM nell'analisi chinasica, rispettivamente. LDN-193189 inibisce l'attività trascrizionale dei recettori BMP di tipo I ALK2 e ALK3 con IC50 di 5 nM e 30 nM in cellule C2C12, rispettivamente, esibisce una selettività 200 volte superiore per BMP rispetto a TGF-β. Per i test cellulari, si raccomanda l'S7507 LDN-193189 2HCl idrosolubile. Questo prodotto ha scarsa solubilità, sono disponibili esperimenti sugli animali, si prega di scegliere attentamente per gli esperimenti sulle cellule! |
|
|
| S7692 | A-83-01 | A-83-01 è un potente inibitore del recettore TGF-β di tipo I (ALK5-TD) con una IC50 di 12 nM. Questo composto inibisce anche la trascrizione indotta dal recettore di tipo I di activina/nodale (ALK4-TD) e dal recettore di tipo I nodale (ALK7-TD) con IC50 di 45 nM e 7,5 nM, rispettivamente.Le soluzioni sono instabili e devono essere preparate al momento. |
|
|
| S7507 | LDN-193189 Dihydrochloride | LDN-193189 (DM3189) 2HCl è un inibitore selettivo della segnalazione BMP, inibisce ALK1, ALK2, ALK3 e ALK6 con IC50 di 0,8 nM, 0,8 nM, 5,3 nM e 16,7 nM nel saggio chinasico, rispettivamente. LDN-193189 inibisce l'attività trascrizionale dei recettori BMP di tipo I ALK2 e ALK3 con IC50 di 5 nM e 30 nM nelle cellule C2C12, rispettivamente, e mostra una selettività 200 volte superiore per BMP rispetto a TGF-β. |
|
|
| S2230 | Galunisertib (LY2157299) | Galunisertib (LY2157299) è un potente inibitore del recettore I di TGFβ (TβRI / ALK5) con una IC50 di 56 nM in un saggio senza cellule. Fase 2/3. |
|
|
| S6654 | SRI-011381 (C381) | SRI-011381 (C381), un nuovo agonista della via di segnalazione TGF-beta per il trattamento della malattia di Alzheimer, si rivolge fisicamente al lisosoma, promuove l'acidificazione lisosomiale, aumenta la degradazione del carico lisosomiale e migliora la resilienza del lisosoma ai danni. |
|
|
| S2704 | LY2109761 | LY2109761 è un nuovo inibitore duale selettivo del recettore di tipo I/II del TGF-β (TβRI/II) con Ki di 38 nM e 300 nM in un saggio acellulare, rispettivamente; è stato dimostrato che influenza negativamente la fosforilazione di Smad2. Questo composto blocca l'autophagy e induce l'apoptosis. |
|
|
| S7959 | SIS3 Hydrochloride | SIS3, un nuovo inibitore specifico di Smad3, inibisce la segnalazione di TGF-β e attivina sopprimendo la fosforilazione di Smad3 senza influenzare le vie di segnalazione MAPK/p38, ERK o PI3-chinasi. |
|
|
The TGF-β/Smad signaling pathway: Core mechanisms and regulation
To contextualize the design and function of TGF-beta/Smad inhibitors, a foundational understanding of the TGF-β/Smad signaling pathway is essential. The pathway is activated by the binding of TGF-β ligands (TGF-β1, TGF-β2, TGF-β3) to transmembrane serine/threonine kinase receptors (TGFBR1/ALK5 and TGFBR2), which form a heterotetrameric complex upon ligand engagement.
Smad protein-mediated canonical signaling
Upon receptor activation, the intracellular Smad proteins—classified as receptor-regulated Smads (R-Smads: Smad2, Smad3), common-mediator Smad (Co-Smad: Smad4), and inhibitory Smads (I-Smads: Smad6, Smad7)—orchestrate the canonical signaling cascade. Phosphorylation of Smad2/3 by TGFBR1 triggers their dissociation from the receptor and heterodimerization with Smad4. This Smad complex translocates to the nucleus, where it interacts with transcription factors, co-activators, or co-repressors to regulate the expression of target genes involved in cell proliferation, differentiation, and apoptosis. I-Smads (Smad6/7) act as negative regulators by binding to activated TGFBR1, preventing R-Smad phosphorylation, or promoting ubiquitination and degradation of receptor complexes.
Non-canonical crosstalk and pathway plasticity
Beyond Smad-dependent signaling, TGF-β engages non-canonical pathways (e.g., MAPK, PI3K/Akt, Wnt / β-catenin) that modulate Smad function and expand the pathway’s biological output. This crosstalk is cell-type and context-dependent, and dysregulation of these interactions is a hallmark of pathological states. For example, in epithelial cells, TGF-β-induced Smad3 activation represses MYC expression to inhibit proliferation, while in mesenchymal cells, Smad3 cooperates with NF-κB to promote pro-fibrotic gene expression. Understanding this plasticity is critical for developing TGF-beta/Smad inhibitors that target disease-specific signaling nodes without disrupting physiological homeostasis.
Function of TGF-beta/Smad inhibitors in disease models
TGF-beta/Smad inhibitors are engineered to disrupt aberrant TGF-β/Smad signaling, with preclinical research focusing on two major disease areas: cancer and fibrosis. These inhibitors act through diverse mechanisms, including receptor kinase inhibition, Smad protein sequestration, and antisense targeting of TGF-β or Smad gene transcripts.
Anti-cancer activity of TGF-beta/Smad inhibitors
The dual role of TGF-β in cancer creates a paradox for therapeutic targeting: while early-stage tumors benefit from TGF-β’s tumor-suppressive effects, advanced metastatic disease is driven by TGF-β-mediated epithelial-mesenchymal transition (EMT), immune suppression, and angiogenesis. TGF-beta/Smad inhibitors address this by selectively blocking the pro-tumorigenic arm of the pathway. Preclinical studies have demonstrated that small-molecule ALK5 inhibitors (e.g., galunisertib, SB431542) suppress Smad2/3 phosphorylation in breast, lung, and pancreatic cancer models, reversing EMT and reducing metastatic burden. Additionally, Smad4-targeted inhibitors disrupt the nuclear translocation of Smad complexes, inhibiting the expression of pro-metastatic genes such as SNAI1 and TWIST1. Combination therapies—pairing TGF-beta/Smad inhibitors with immune checkpoint blockers (e.g., anti-PD-1)—have shown synergistic effects by reversing TGF-β-mediated immune evasion in the tumor microenvironment, restoring cytotoxic T-cell infiltration and activity. However, challenges remain, including dose-limiting toxicities (e.g., gastrointestinal perforation) due to off-target inhibition of physiological TGF-β signaling in normal tissues.
Anti-fibrotic effects of TGF-beta/Smad inhibitors
Fibrosis is characterized by excessive ECM deposition, driven by persistent TGF-β/Smad signaling in fibroblasts and myofibroblasts. TGF-beta/Smad inhibitors target this by blocking Smad3-mediated transcription of pro-fibrotic genes (e.g., COL1A1, CTGF, TIMP1) that encode collagens and ECM remodeling enzymes. In preclinical models of lung, liver, and renal fibrosis, ALK5 inhibitors reduce Smad3 phosphorylation and collagen accumulation, improving organ function and reducing scar tissue formation. Antisense oligonucleotides targeting TGF-β1 mRNA or Smad3 gene expression have shown specificity and reduced off-target effects compared to small-molecule inhibitors, as they directly silence the expression of key pathway components. For example, a Smad3 antisense oligonucleotide (SIS3) has been shown to prevent renal fibrosis in diabetic nephropathy models by inhibiting Smad3 binding to the COL1A1 promoter, without affecting Smad2 or Smad4 function. However, long-term efficacy is limited by the adaptive upregulation of alternative pro-fibrotic pathways (e.g., YAP /TAZ), highlighting the need for combinatorial inhibition of Smad-dependent and independent signaling.
Gene-targeted TGF-beta/Smad inhibitors: Next-generation strategies
Advancements in gene editing and nucleic acid therapeutics have enabled the development of precision TGF-beta/Smad inhibitors that target the genetic drivers of pathway dysregulation. These approaches offer improved specificity compared to small-molecule inhibitors, reducing off-target effects and enhancing therapeutic windows.
CRISPR/Cas9-mediated knockout of Smad and TGF-β pathway genes
CRISPR/Cas9 technology allows for the targeted knockout of Smad genes (e.g., SMAD3, SMAD4) or TGF-β receptor genes (TGFBR1, TGFBR2) in diseased cells, providing a tool to dissect pathway function and validate therapeutic targets. In preclinical cancer models, CRISPR-mediated SMAD4 knockout in pancreatic cancer cells abrogates Smad complex formation, inhibiting tumor growth and sensitizing cells to chemotherapy. Similarly, SMAD3 knockout in fibrotic liver models reduces pro-fibrotic gene expression and ECM deposition, reversing liver cirrhosis. While gene editing is currently limited to ex vivo applications (e.g., autologous cell therapy), in vivo delivery systems (e.g., lipid nanoparticles, viral vectors) are being optimized to enable systemic targeting of TGF-beta/Smad pathway genes.
RNA-based inhibitors of Smad gene expression
Small interfering RNAs (siRNAs) and microRNAs (miRNAs) targeting Smad or TGF-β gene transcripts represent a promising class of TGF-beta/Smad inhibitors. siRNAs against SMAD2/3 or TGFB1 have been shown to silence target gene expression in vitro and in vivo, reducing Smad phosphorylation and pro-fibrotic/cancer-associated gene expression. For example, lipid nanoparticle-delivered siRNA targeting TGFB1 has demonstrated efficacy in murine lung fibrosis models, with sustained reduction in TGF-β1 protein levels and collagen deposition for up to 4 weeks post-administration. miRNAs such as miR-29, which represses COL1A1 and SMAD3 expression, are being explored as endogenous TGF-beta/Smad inhibitors; replacement of miR-29 in fibrotic tissues restores its anti-fibrotic function, complementing exogenous inhibitor therapies.
Translational challenges and future directions
Despite robust preclinical data, translating TGF-beta/Smad inhibitors to clinical practice faces significant hurdles. First, the context-dependent function of TGF-β requires patient stratification—biomarkers such as Smad4 expression, TGF-β ligand levels, or EMT status are needed to identify patients most likely to benefit from inhibition. Second, systemic inhibition of TGF-β signaling can lead to adverse effects (e.g., impaired wound healing, increased infection risk) due to the pathway’s role in immune regulation and tissue repair. Tissue-specific delivery systems (e.g., antibody-drug conjugates, nanoparticle targeting) are being developed to restrict inhibitor activity to diseased tissues. Third, resistance to TGF-beta/Smad inhibitors is emerging as a challenge, driven by adaptive upregulation of alternative signaling pathways or mutations in Smad genes (e.g., SMAD4 loss in colorectal cancer). Combinatorial strategies targeting both Smad-dependent and independent pathways are being tested to overcome resistance.Looking forward, single-cell RNA sequencing and spatial transcriptomics are enabling the identification of cell-type-specific Smad gene expression patterns, facilitating the design of inhibitors tailored to distinct disease microenvironments. Additionally, personalized medicine approaches—using patient-derived organoids to test TGF-beta/Smad inhibitor efficacy—are improving the predictability of clinical outcomes. As our understanding of TGF-β/Smad signaling complexity deepens, TGF-beta/Smad inhibitors are poised to move from preclinical research to clinical application, offering new hope for patients with cancer and fibrotic disorders.
I prodotti sono solo per uso di ricerca. Non per uso umano. Non vendiamo a pazienti.
©Copyright 2013 Selleck Chemicals. Tutti i diritti riservati.